羟氯喹治疗下调原发性干燥综合征系统性干扰素活化:JOQUER随机试验
JOQUER随机试验纳入77例原发性干燥综合征患者,接受羟氯喹400 mg/d或安慰剂治疗24周。羟氯喹显著降低I型干扰素评分和干扰素刺激基因表达,并降低ESR、IgG和IgM水平,但未改善EULAR SS疾病活动指数或患者报告指数。
要点
- 羟氯喹400 mg/d治疗24周可下调原发性干燥综合征患者I型干扰素评分和ISG表达。
- 羟氯喹降低ESR、IgG和IgM水平,且不依赖患者干扰素活化状态。
- 羟氯喹未改善ESSDAI或ESSPRI临床应答,干扰素活化与临床应答无关。
核心结论
- 羟氯喹治疗24周显著降低原发性干燥综合征患者I型干扰素评分和ISG表达,但未改善临床应答。
研究设计与样本
- 研究基于安慰剂对照JOQUER试验,纳入77例原发性干燥综合征患者,治疗24周,羟氯喹400 mg/d或安慰剂。
主要发现
- 与安慰剂组相比,羟氯喹组干扰素评分和ISG表达降低。
- 羟氯喹降低ESR、IgG和IgM水平,且不依赖患者干扰素活化状态。
- 羟氯喹治疗后ESSDAI或ESSPRI评分无差异,即使按干扰素活化分层后亦无差异。
关键数值与推荐
- 羟氯喹剂量为400 mg/d,疗程24周。
- 共77例患者纳入ISG表达和干扰素评分分析。
临床怎么用
- 羟氯喹可下调原发性干燥综合征患者I型干扰素活化和部分实验室指标,但不应期望其改善ESSDAI或ESSPRI临床应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: HCQ is frequently used to treat primary SS (pSS), but evidence for its efficacy is limited. HCQ blocks IFN activation, which is present in half of the pSS patients. The effect of HCQ treatment on the expression of IFN-stimulated genes (ISGs) was studied in pSS. Furthermore, HCQ-treated patients were stratified based on IFN activation and differences in disease activity and clinical parameters were studied. METHODS: Expression of ISGs and IFN scores was determined in 77 patients, who were previously enrolled in the placebo-controlled JOQUER trial. Patients were treated for 24 weeks with 400 mg/d HCQ or placebo. RESULTS: HCQ treatment reduced IFN scores and expression of ISGs compared with the placebo-treated group. HCQ reduced ESR, IgG and IgM levels independently of the patients' IFN activation status. No differences in EULAR SS disease activity index or EULAR SS patient reported index scores were observed after HCQ treatment, even after IFN stratification. CONCLUSION: Treatment for 24 weeks with HCQ significantly reduced type I IFN scores and ISG-expression compared with the placebo-treated group. HCQ reduced several laboratory parameters, but failed to improve clinical response. This suggests that in pSS, type I IFN is associated to some laboratory parameters abnormalities, but not related to the clinical response.
引用
- Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, et al. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 2020. PMID: 31237947. doi:10.1093/rheumatology/kez242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。